| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Zhengye Biotechnology GAAP EPS of -$0.06, revenue of $7.51M | 1 | Seeking Alpha | ||
| 12.11. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.08. | Zhengye Biotechnology regains Nasdaq bid price compliance; shares down | 2 | Seeking Alpha | ||
| 22.07. | Zhengye Biotechnology Stock Plunges Following 322% Rally In Volatile Reversal | 18 | Benzinga.com | ||
| 21.07. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.07. | Morning Market Movers: Zhengye Biotechnology, Lisata Therapeutics, Meiwu Technology, Danaher Corporation See Big Swings | 1.214 | AFX News | WASHINGTON (dpa-AFX) - At 9:00 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 21.07. | Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity | 473 | GlobeNewswire (Europe) | Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| ZHENGYE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 04.06. | Zhengye Biotechnology receives Nasdaq bid price deficiency notice | 2 | Investing.com | ||
| 04.06. | Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 279 | GlobeNewswire (Europe) | Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 04.06. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.04. | Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results | 355 | PR Newswire | JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer... ► Artikel lesen | |
| 06.04. | Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure | 371 | GlobeNewswire (Europe) | Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 10.02. | Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders | 1.035 | GlobeNewswire (Europe) | Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 18,494 | +0,12 % | Viatris Completes Acquisition Of Pacira BioSciences For $36.50 Per Share | ||
| SYNBIOTIC | 0,120 | -9,21 % | SYNBIOTIC SE: Zuvor aufgezeigte Risiken haben sich materialisiert; Rating und Kursziel under review | SYNBIOTIC hat angekündigt, einen Insolvenzantrag zu stellen, nachdem es dem Unternehmen angesichts anhaltend schwieriger Marktbedingungen nicht gelungen ist, eine ausreichende Finanzierung sicherzustellen.... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,631 | +2,27 % | Organigram Global Inc: Organigram has 180 days to cure Nasdaq non-compliance | ||
| QUANTUM BIOPHARMA | 1,419 | +18,25 % | Quantum BioPharma Non-GAAP EPS of -$0.06 | ||
| NEKTAR THERAPEUTICS | 31,890 | +1,59 % | Nektar Therapeutics verfügt über liquide Mittel von 952,9 Millionen US-Dollar - Finanzierungsreichweite bis Mitte 2028 gesichert | ||
| TONIX PHARMACEUTICALS | 2,630 | +2,53 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA | New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,545 | -0,14 % | ORAMED PHARMACEUTICALS INC. - 10-Q, Quarterly Report | ||
| SELLAS LIFE SCIENCES | 16,650 | +1,83 % | Aktie verdreifacht sich: Sellas Life Sciences: Neuer Krebsimpfstoff beflügelt | © Foto: adobe.stock.comDie Aktie von Sellas Life Sciences verzeichnet nach überzeugenden Studiendaten zu einem experimentellen Blutkrebs-Impfstoff einen historischen Kurssprung Enthaltene Werte: US81642T2096Den... ► Artikel lesen | |
| OPKO HEALTH | 1,490 | +3,47 % | Labcorp To Acquire BioReference Health Assets; OPKO Shares Rise 7.35% | WASHINGTON (dpa-AFX) - Labcorp Holdings Inc. (LH), a provider of innovative and comprehensive laboratory services, on Thursday announced that it had agreed to acquire select assets of BioReference... ► Artikel lesen | |
| JAGUAR HEALTH | 0,352 | -0,25 % | Jaguar Health, Inc.: Jaguar Health Reports Third Quarter 2026 Financials | Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,929 | -2,42 % | XORTX THERAPEUTICS GAAP EPS of -$0.21 | ||
| OPUS GENETICS | 3,620 | +1,12 % | Opus Genetics, Inc.: Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 | OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement... ► Artikel lesen | |
| SOLIGENIX | 0,252 | -0,32 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results | PRINCETON, N.J., Nov. 6, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare... ► Artikel lesen | |
| TALPHERA | 0,730 | 0,00 % | Talphera outlines plan to seek FDA agreement to end NEPHRO enrollment by Dec. 31, 2026, while raising Niyad peak U.S. sales view to over $200M | ||
| SAVARA | 4,353 | +0,90 % | H.C. Wainwright initiates Savara stock coverage with buy rating |